Skip to content

Study · Animal study (in vivo) · rat · 1998

12 results

Brain-derived peptides reduce the size of cerebral infarction and loss of MAP2 immunoreactivity after focal ischemia in rats.

Schwab M, Antonow-Schlorke I, Zwiener U, Bauer R

Journal of neural transmission. Supplementum1 Jan 1998Cited by 18 (Europe PMC)

PMID9700666 (opens in a new tab)DOI10.1007/978-3-7091-6467-9_26 (opens in a new tab)PepBankPUB-09700666
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with focal ischemia, local cortical blood flow did not differ between Cerebrolysin and untreated controls.

    In plain wordsIn rats with focal brain ischemia, Cerebrolysin did not change cortical blood flow compared with untreated controls.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeLocal cortical blood flow
    Study

    ratn = 13

    Male Thomae rats with reversible middle cerebral artery occlusion
    Comparator
    Untreated ischemic controls
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No differences in LCBF between the control and the BDP-treated animals were found.
    1 context sentence
    Summary · context
    Male Thomae rats were divided randomly into a sham-operated group (n = 5), an ischemic control (untreated) group (n = 7) and an ischemic BDP-treated group (n = 6) and subjected to reversible middle cerebral artery occlusion (MCAO) for 2h followed by 90min of reperfusion.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with focal ischemia, Cerebrolysin reduced subiculum MAP2 immunoreactivity loss by 59% versus controls.

    In plain wordsIn rats with focal brain ischemia, Cerebrolysin reduced subiculum neuronal marker loss compared with controls.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseSubiculum MAP2 immunoreactivity loss
    Study

    ratn = 13

    Male Thomae rats with reversible middle cerebral artery occlusion
    Comparator
    Untreated ischemic controls
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    MAP2 loss reduction
    59%
    subiculum

    Source sentences

    Summary
    In the hippocampus, BDP-treated animals showed a significant reduction of loss of MAP2 immunoreactivity in the subiculum and CA1 region by 59% and 64%, respectively, in comparison to control animals (p < 0.05).
    1 context sentence
    Summary · context
    Male Thomae rats were divided randomly into a sham-operated group (n = 5), an ischemic control (untreated) group (n = 7) and an ischemic BDP-treated group (n = 6) and subjected to reversible middle cerebral artery occlusion (MCAO) for 2h followed by 90min of reperfusion.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with focal ischemia, Cerebrolysin reduced CA1 MAP2 immunoreactivity loss by 64% versus controls.

    In plain wordsIn rats with focal brain ischemia, Cerebrolysin reduced CA1 neuronal marker loss compared with controls.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseCA1 MAP2 immunoreactivity loss
    Study

    ratn = 13

    Male Thomae rats with reversible middle cerebral artery occlusion
    Comparator
    Untreated ischemic controls
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    MAP2 loss reduction
    64%
    CA1

    Source sentences

    Summary
    In the hippocampus, BDP-treated animals showed a significant reduction of loss of MAP2 immunoreactivity in the subiculum and CA1 region by 59% and 64%, respectively, in comparison to control animals (p < 0.05).
    1 context sentence
    Summary · context
    Male Thomae rats were divided randomly into a sham-operated group (n = 5), an ischemic control (untreated) group (n = 7) and an ischemic BDP-treated group (n = 6) and subjected to reversible middle cerebral artery occlusion (MCAO) for 2h followed by 90min of reperfusion.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with focal ischemia, Cerebrolysin tended to reduce irreversibly damaged neurons in the subiculum and CA1 versus controls.

    In plain wordsIn rats with focal brain ischemia, Cerebrolysin tended to reduce irreversible hippocampal neuron damage compared with controls.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseIrreversibly damaged hippocampal neurons
    Study

    ratn = 13

    Male Thomae rats with reversible middle cerebral artery occlusion
    Comparator
    Untreated ischemic controls
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The amount of irreversibly damaged neurons in these regions was decreased in tendency.
    2 context sentences
    Summary · context
    In the hippocampus, BDP-treated animals showed a significant reduction of loss of MAP2 immunoreactivity in the subiculum and CA1 region by 59% and 64%, respectively, in comparison to control animals (p < 0.05).
    Summary · context
    Male Thomae rats were divided randomly into a sham-operated group (n = 5), an ischemic control (untreated) group (n = 7) and an ischemic BDP-treated group (n = 6) and subjected to reversible middle cerebral artery occlusion (MCAO) for 2h followed by 90min of reperfusion.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with focal ischemia, Cerebrolysin reduced neuronal injury in the inner dentate gyrus blade by 98%.

    In plain wordsIn rats with focal brain ischemia, Cerebrolysin reduced dentate gyrus neuron injury compared with untreated controls.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseDentate gyrus neuronal injury
    Study

    ratn = 13

    Male Thomae rats with reversible middle cerebral artery occlusion
    Comparator
    Untreated ischemic controls
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Neuronal injury reduction
    98%
    inner dentate gyrus blade

    Source sentences

    Summary
    However, the inner blade of the dentate gyrus in BDP-treated animals showed a significant reduction of neuronal injury by 98% (p < 0.05).
    1 context sentence
    Summary · context
    Male Thomae rats were divided randomly into a sham-operated group (n = 5), an ischemic control (untreated) group (n = 7) and an ischemic BDP-treated group (n = 6) and subjected to reversible middle cerebral artery occlusion (MCAO) for 2h followed by 90min of reperfusion.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with focal ischemia, Cerebrolysin reduced thalamic and hypothalamic MAP2 loss areas by 51%.

    In plain wordsIn rats with focal brain ischemia, Cerebrolysin reduced thalamic and hypothalamic neuronal marker loss compared with controls.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseThalamic and hypothalamic MAP2 loss area
    Study

    ratn = 13

    Male Thomae rats with reversible middle cerebral artery occlusion
    Comparator
    Untreated ischemic controls
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    MAP2 loss area reduction
    51%
    thalamic and hypothalamic structures

    Source sentences

    Summary
    Likewise, BDP treatment reduced the size of the areas showing a loss of MAP2 immunoreactivity in the thalamic and hypothalamic structures by 51% and in the mesencephalon by 81% (p < 0.05).
    1 context sentence
    Summary · context
    Male Thomae rats were divided randomly into a sham-operated group (n = 5), an ischemic control (untreated) group (n = 7) and an ischemic BDP-treated group (n = 6) and subjected to reversible middle cerebral artery occlusion (MCAO) for 2h followed by 90min of reperfusion.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with focal ischemia, Cerebrolysin reduced mesencephalon MAP2 loss areas by 81%.

    In plain wordsIn rats with focal brain ischemia, Cerebrolysin reduced midbrain neuronal marker loss compared with untreated controls.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseMesencephalon MAP2 loss area
    Study

    ratn = 13

    Male Thomae rats with reversible middle cerebral artery occlusion
    Comparator
    Untreated ischemic controls
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    MAP2 loss area reduction
    81%
    mesencephalon

    Source sentences

    Summary
    Likewise, BDP treatment reduced the size of the areas showing a loss of MAP2 immunoreactivity in the thalamic and hypothalamic structures by 51% and in the mesencephalon by 81% (p < 0.05).
    1 context sentence
    Summary · context
    Male Thomae rats were divided randomly into a sham-operated group (n = 5), an ischemic control (untreated) group (n = 7) and an ischemic BDP-treated group (n = 6) and subjected to reversible middle cerebral artery occlusion (MCAO) for 2h followed by 90min of reperfusion.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats with focal ischemia, Cerebrolysin tended to reduce infarct areas in the reported subcortical regions versus controls.

    In plain wordsIn rats with focal brain ischemia, Cerebrolysin tended to reduce subcortical infarct areas compared with controls.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseSubcortical infarct area
    Study

    ratn = 13

    Male Thomae rats with reversible middle cerebral artery occlusion
    Comparator
    Untreated ischemic controls
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The size of the infarcted areas in these regions (H&E) was reduced in tendency.
    2 context sentences
    Summary · context
    Likewise, BDP treatment reduced the size of the areas showing a loss of MAP2 immunoreactivity in the thalamic and hypothalamic structures by 51% and in the mesencephalon by 81% (p < 0.05).
    Summary · context
    Male Thomae rats were divided randomly into a sham-operated group (n = 5), an ischemic control (untreated) group (n = 7) and an ischemic BDP-treated group (n = 6) and subjected to reversible middle cerebral artery occlusion (MCAO) for 2h followed by 90min of reperfusion.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats with focal ischemia, Cerebrolysin showed no proven protective effect in the caudate putamen.

    In plain wordsIn rats with focal brain ischemia, Cerebrolysin showed no proven caudate putamen protection compared with untreated controls.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedCaudate putamen protection
    Study

    ratn = 13

    Male Thomae rats with reversible middle cerebral artery occlusion
    Comparator
    Untreated ischemic controls
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the caudate putamen, no protective effect of BDP-treatment could be proven.
    1 context sentence
    Summary · context
    Male Thomae rats were divided randomly into a sham-operated group (n = 5), an ischemic control (untreated) group (n = 7) and an ischemic BDP-treated group (n = 6) and subjected to reversible middle cerebral artery occlusion (MCAO) for 2h followed by 90min of reperfusion.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In rats with focal ischemia, hemisphere volume increased by 8 +/- 1% with Cerebrolysin and 10 +/- 1% in controls.

    In plain wordsIn rats with focal brain ischemia, hemisphere swelling occurred with Cerebrolysin and in untreated controls.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableIschemic hemisphere volume increase
    Study

    ratn = 13

    Male Thomae rats with reversible middle cerebral artery occlusion
    Comparator
    Untreated ischemic controls
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Hemisphere volume increase
    8%
    BDP-treated
    Hemisphere volume increase
    10%
    control

    Source sentences

    Summary
    Cerebral infarction was accompanied by an increase in the volume of the ischemic hemisphere by 10 +/- 1% in the control and 8 +/- 1% in the BDP-treated animals.
    1 context sentence
    Summary · context
    Male Thomae rats were divided randomly into a sham-operated group (n = 5), an ischemic control (untreated) group (n = 7) and an ischemic BDP-treated group (n = 6) and subjected to reversible middle cerebral artery occlusion (MCAO) for 2h followed by 90min of reperfusion.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In rats with focal ischemia, peripheral cortical blood flow fell to 55 to 65% of baseline without a reported treatment-specific difference.

    In plain wordsIn rats with brain ischemia, peripheral brain blood flow fell during ischemia, without a reported difference between Cerebrolysin and control groups.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseLocal cortical blood flow during ischemia
    Study

    ratn: not reported in source

    Reversible middle cerebral artery occlusion
    Comparator
    Baseline
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Local cortical blood flow
    55 to 65 % of baseline
    Periphery of infarcted areas

    Source sentences

    Summary
    LCBF was estimated from the periphery of infarcted areas and was reduced to 55 to 65% of baseline values (p < 0.05).
    2 context sentences
    Summary · context
    No differences in LCBF between the control and the BDP-treated animals were found.
    Summary · context
    Male Thomae rats were divided randomly into a sham-operated group (n = 5), an ischemic control (untreated) group (n = 7) and an ischemic BDP-treated group (n = 6) and subjected to reversible middle cerebral artery occlusion (MCAO) for 2h followed by 90min of reperfusion.
  12. 12AnimalAnimal study (in vivo)Mechanism

    In rats with focal ischemia, reperfusion restored cortical blood flow to baseline without a reported difference between Cerebrolysin and control groups.

    In plain wordsIn rats with brain ischemia, blood flow returned to baseline after reperfusion, without a reported difference between Cerebrolysin and control groups.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseLocal cortical blood flow after reperfusion
    Study

    ratn: not reported in source

    Reversible middle cerebral artery occlusion
    Comparator
    Ischemic blood flow
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Reperfusion led to LCBF being increased again to baseline values.
    2 context sentences
    Summary · context
    No differences in LCBF between the control and the BDP-treated animals were found.
    Summary · context
    Male Thomae rats were divided randomly into a sham-operated group (n = 5), an ischemic control (untreated) group (n = 7) and an ischemic BDP-treated group (n = 6) and subjected to reversible middle cerebral artery occlusion (MCAO) for 2h followed by 90min of reperfusion.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.